Oncolytics Biotech (ONCY) and SOLTI Present Clinical Breast Cancer Data Highlighting Pelareorep-Induced Anti-Tumor T Cell Responses at SITC

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. MU
3. ACN
4. IBM
5. DPZ
6. PRIM
7. META
8. N2EW34
9. INTC
10. IMNN

Go back to Oncolytics Biotech (ONCY) and SOLTI Present Clinical Breast Cancer Data Highlighting Pelareorep-Induced Anti-Tumor T Cell Responses at SITC

Oncolytics Biotech® and SOLTI Present Clinical Breast Cancer Data Highlighting Pelareorep-Induced Anti-Tumor T Cell Responses at The Society for Immunotherapy of Cancer Annual Meeting

November 9, 2020 8:05 AM EST

- AWARE-1 data support the results of a prior phase 2 trial that showed a near doubling of overall survival with pelareorep treatment in HR+/HER2- breast cancer patients

- Data show pelareorep-induced generation and expansion of anti-tumor T cell clones that may contribute to a durable anti-cancer immune memory effect and improve outcomes in breast cancer

- 70% of cohort-1 patients saw an increase in CelTIL, the study's primary endpoint and a measure of tumor inflammation that is associated with favorable clinical outcomes

SAN DIEGO, CA and CALGARY, AB, Nov. 9, 2020... More